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Abstract
Objective To examine the attitudes of US patients about the use of
placebo treatments in medical care.
Design One time telephone surveys.
Setting Northern California.
Participants 853 members of Kaiser Permanente Northern California,
aged 18-75, who had been seen by a primary care provider for a chronic
health problem at least once in the prior six months.
Results The response rate was 53.4% (853/1598) of all members who
were eligible to participate, and 73.2% (853/1165) of all who could be
reached by telephone. Most respondents (50-84%) judged it acceptable
for doctors to recommend placebo treatments under conditions that
varied according to doctors’ level of certainty about the benefits and
safety of the treatment, the purpose of the treatment, and the
transparency with which the treatment was described to patients. Only
21.9% of respondents judged that it was never acceptable for doctors
to recommend placebo treatments. Respondents valued honesty by
physicians regarding the use of placebos and believed that
non-transparent use could undermine the relationship between patients
and physicians.
ConclusionsMost patients in this survey seemed favorable to the idea
of placebo treatments and valued honesty and transparency in this
context, suggesting that physicians should consider engaging with
patients to discuss their values and attitudes about the appropriateness
of using treatments aimed at promoting placebo responses in the context
of clinical decision making.
Introduction
Several recent surveys of physicians have documented their use
of placebo treatments in clinical practice.1-4 In a recent US survey
of internists and rheumatologists, half reported that they have
prescribed placebo treatments, defined as treatments “whose
benefits derive from positive patient expectations rather than
from the physiologic or pharmacologic mechanism of the
treatment itself.”4 These placebo treatments included active
agents (more often than inert substances) such as vitamins or
analgesics that a physician prescribed to promote positive
placebo effects rather than specific pharmacologic or physiologic
effects. How these surveys described placebo treatments varied
considerably, suggesting that there are conceptual nuances
regarding the use of such treatments in clinical care that need
to be better understood.5 Although some distinguish between
pure and impure (or inert and active) placebos, it is the lack of
specific efficacy that is based on the inherent properties of a
compound that makes an intervention a placebo.6
The prescription of placebo treatments as part of medical care
is ethically controversial. Their use has been criticized because
the practice is thought to involve deception, thereby violating
patient autonomy,7 8 because of concerns about the compatibility
of placebo treatments with evidence based medicine, and
because the risks introduced by some placebo treatments
outweigh the possible benefits of their use, as in the case of
prescribing antibiotics for viral infection.9 US clinical practice
guidelines prohibit the use of placebo treatments without a
patient’s knowledge, citing concerns about undermining trust
and compromising the patient-physician relationship.10 Despite
these concerns, some have argued that use of placebo treatments
can be justified when they are effective, at least in certain
cases.11 12 Furthermore, some placebo treatments may be
effective without the use of deception.13 A recent randomized
trial of open “inert” placebo pills in patients with irritable bowel
syndrome, offered without deception but with the suggestion
of benefit from the placebo response, found clinically significant
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improvement of symptoms compared with those receiving no
treatment.14
The perspectives of US patients have been missing in the debate
over the use of placebo treatments in clinical practice. Although
one study explored how US participants in clinical trials
conceptualize the placebo effect,15 little research has examined
how patients think about placebo treatments. Surveys in other
countries have described patients’ attitudes toward use of
placebo treatments.3 16-18 These studies suggest that patients are
open to the use of placebo treatments in specific circumstances,
sometimes even more so than clinicians, although they wish to
be informed about the receipt of such therapies. However, the
generalizability of the findings needs to be interpreted
cautiously, given cultural differences and the various definitions
of “placebo treatment” used in the surveys.
Data on patients’ perspectives are essential to understanding
this issue and formulating rational clinical policies. For example,
if patients are generally accepting of their physicians’ use of
placebos, then the ethical perspectives on placebo use may need
to be reconsidered. If patients are generally opposed to placebo
use, then many physicians may need more education about their
behavior with respect to their clinical use of placebos. And if
there exists large variation in patients’ viewpoints, physicians
will need to learn how to elicit their patients’ perspectives to
act in concert with their desires; in this case, blanket prohibition
of clinical placebo use may be misguided.
To probe the attitudes of US patients regarding placebo
treatments, we conducted a survey of adult members of a large
Northern California health plan. Our survey utilized a carefully
constructed definition of “placebo treatments,” used a
combination of general questions and detailed scenarios, and
included a large and demographically diverse sample of patients.
Methods
The sample for this survey was adult members of Kaiser
Permanente Northern California aged 18-75 who had been seen
in an outpatient clinic for a chronic health problem at least once
in the prior six months. The demographic and health
characteristics of the Kaiser Permanente Northern California
adult population are similar to the population of insured adults
in Northern California, with the exception of a smaller
percentage of adults at low levels of educational attainment.19
After assigning all eligible members a random study identifier,
we randomly selected an age stratified sample (10 year age
groups), with members contacted to participate in the survey in
consecutive numerical order from the randomly generated list.
An introductory letter described the study goals and offered
members an opportunity to opt out of the study. We telephoned
those who did not opt out and asked them to complete the survey
by phone. We excluded people who had dementia or could not
participate in a telephone interview because of communication
barriers (hearing, language). Potential participants were
telephoned up to five times before being dropped from the
survey pool. Respondents were sent a $20 (£13; €15) gift card
after participating in the interview. Participants gave informed
consent before taking part in the survey.
The survey was developed through a process that included
patient focus groups in Baltimore, Maryland, expert review,
and pretesting of the telephone interviews with 20 members of
Kaiser Permanente Northern California. Trained interviewers
administered the survey using a computer aided telephone
interview system, which took respondents an average of 20
minutes to complete. Respondents were initially asked about
their beliefs regarding the connection between the mind, body,
and illness, and their knowledge of placebos and the placebo
effect. They were then provided with an operational definition
of “placebo treatment”: “A patient experiences a placebo effect
when they get better after taking a treatment, not because of the
treatment itself, but because the patient expects they will benefit
from the treatment. For the rest of this survey, we will ask you
to assume that a placebo treatment is a treatment that only works
because it can produce a placebo effect. Placebo treatments can
be sugar pills or other treatments used to create a placebo effect.”
This definition was based on previous surveys of physicians
and our experience with patient focus groups.
Following this explanation, we asked respondents about their
beliefs regarding placebo mechanisms and the acceptability of
doctors recommending placebo treatments, using both general
questions and scenarios that varied the nature of the placebo
treatment, the treatment indication, and the manner in which
the physician described the treatment to the patient. Respondents
were randomized to two different versions of scenario 1 (box),
which varied according to whether or not the patient was aware
that the doctor was recommending a placebo treatment.
Respondents were also asked about their willingness to take
placebos in different scenarios.
Statistical analysis
We analyzed data using SAS version 9.1. For most variables,
responses were collapsed into positive (definitely or probably
yes, strongly or somewhat agree) versus negative (probably or
definitely not, somewhat or strongly disagree), or one extreme
(for example, definitely yes) versus other. To test for
significance we used the TTest Procedure (two sided tests). We
considered a P value of <0.05 to be significant.
Results
Of 1800 letters mailed, 1598 members were both reachable by
mail and potentially eligible to participate. Of these, 853
completed the telephone interview, 312 refused to participate,
419 were not reachable by telephone after five attempts, and 14
were not interviewed because the target number had been
reached. The response rate was 53.4% of all people who were
potentially eligible to participate (853/1598) and 73.2%
(853/1165) of all who could be reached by phone.
Non-respondents did not differ significantly from respondents,
except for a somewhat greater proportion of women among the
respondents.
Respondent characteristics
Respondents were primarily women (n=524, 61.4%), with an
average age of 45 years. At least an undergraduate college
education was attained by 43.6% (n=372). Although all
respondents had been seen by a doctor for one or more chronic
conditions, most reported being in excellent (n=170, 19.9%) or
very good (n=359, 42.1%) health (table 1⇓).
Mind-body influences on health
Most respondents believed that a person’s mind can affect their
health (96.4%, 95% confidence interval 95.1% to 97.6%), that
thinking positively can improve the physical symptoms of an
illness (9.51%, 89.6% to 93.4%), and that a doctor speaking
positively about a medicine or medical treatment can have at
least a fair amount of influence on the patient’s response to that
treatment (85.0%, 82.6% to 87.4%).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f3757 doi: 10.1136/bmj.f3757 (Published 2 July 2013) Page 2 of 9
RESEARCH
Scenarios regarding use of placebo treatments
Scenario 1
A 45 year old man goes to his doctor because he has been having moderate stomach pains for the past month. After conducting the
appropriate tests, the doctor feels confident that the problem is not serious, even though the cause of the pain is not clear.
Version 1 (430 participants randomized): patient does not know that the doctor is recommending a placebo treatment—The doctor
decides to recommend a safe herbal treatment that does not contain anything likely to relieve the patient’s symptoms, hoping that it
might help by promoting a placebo effect. The doctor doesn’t tell the patient that this is a placebo treatment, just that it is worth trying
as some patients experiencing similar stomach pains get better after taking this treatment. The patient is told to call the doctor if he does
not feel better after taking the medicine for three days.
Version 2 (421 participants randomized): patient is aware that the doctor is recommending the medicine to bring out a placebo effect—The
doctor decides to recommend a safe herbal treatment. He tells the patient that this treatment does not contain any ingredients likely to
relieve his symptoms but it might help by promoting a placebo effect and that some patients experiencing similar stomach pains get
better after taking this treatment. The patient is told to call the doctor if he does not feel better after taking the medicine for three days.
Scenario 2 (all participants)
A 28 year old woman goes to her doctor because of cold symptoms that she has had for about a week. The doctor tells her that she
should not worry and to drink plenty of fluids, get enough sleep, and use over the counter medicines for her symptoms. However, the
patient asks the doctor to recommend antibiotics to treat her cold symptoms. The doctor knows that antibiotics are not effective in treating
a viral infection, which is most likely the cause of the patient’s symptoms. The doctor knows that the patient expects to be given some
medicine to treat her cold. Instead of antibiotics, the doctor decides to recommend a placebo pill. The doctor tells the patient: “I would
like to recommend some medicine that might help you. It is safe and has no side effects. Some people get better when they take it, and
I’d like you to try it.”
Scenario 3 (all participants)
In a recent study published in a medical journal, a group of patients with chronic abdominal pain were given placebo pills after it was
first determined that none of these patients had a serious medical problem. The patients were told that the pills were placebos, like
sugar pills, but had been shown in clinical studies to produce relief through mind-body self healing processes. The study found that
those patients who were given the placebo pills had better symptom relief than a comparison group of patients who did not receive any
placebo pills.
Scenario 4 (all participants)
A patient asks their doctor about a treatment that the doctor considers to be no better than a placebo—for example, an anti-aging cream
or a herbal treatment to manage arthritis or symptoms of an enlarged prostate. The doctor has to decide whether to give an honest
opinion of the treatment. We shall assume that the doctor thinks that the treatment is safe.
Familiarity with placebo terminology and how
placebo treatments work
While 80.7% (78.0% to 83.3%) of respondents were familiar
with the term “placebo” prior to being provided the definition,
only 51.5% (48.1% to 54.8%) had heard the term “placebo
effect.” Approximately two thirds (69.4%, 66.3% to 72.5%) of
respondents believed that placebo treatments can produce
physical changes in the body (table 2⇓). Respondents were asked
several questions about the extent to which they believe placebos
are effective when patients either do or do not know they are
receiving a placebo treatment. Over 80% (83.1%, 80.5% to
85.7%) of respondents believed that placebo treatments can
only be effective if patients do not know that they are receiving
a placebo treatment and trust the physician who is
recommending the treatment (81.0%, 78.3% to 83.6%) (table
2). However, in response to scenario 3 reflecting the randomized
trial of open placebo in patients with irritable bowel syndrome
(box),14 63.9% (59.3% to 68.6%) thought that a placebo
treatment might work to relieve a patient’s stomach pain even
if the patient knew it was a placebo.
General acceptability of prescribing placebo
treatments
Only 21.9% (19.1% to 24.7%) of respondents judged that it was
never acceptable for doctors to recommend placebo treatments
(table 2). While 76.2% (73.4% to 79.1%) judged it was
acceptable for doctors to recommend a placebo treatment if they
thought it would benefit and not harm the patient, fewer (50.1%,
46.7% to 53.4%) considered it acceptable if doctors were
uncertain of the benefit. Approximately 70.0% (66.9% to 73.1%)
stated it was acceptable for doctors to offer a safe placebo
treatment if it addressed the need of patients to feel like they
were being given something to get better. Respondents were
divided in their views about whether doctors should call a
placebo treatment “real medicine”; 46.4% (43.0% to 49.8%)
agreed and 53.6% (50.2% to 57.0%) disagreed that it is
acceptable for physicians to do so (table 2).
Approximately 74.7% (71.8% to 77.6%) of respondents thought
it would be acceptable for a physician to offer a safe placebo
treatment for moderate stomach pain of unknown cause that the
doctor believed was not serious (both versions of scenario 1;
table 3⇓), and 65.6% (62.3% to 68.8%) thought it would be
acceptable to offer a safe placebo treatment for someone who
instead had wanted a prescription for antibiotics for cold
symptoms (scenario 2; table 3). In that scenario, 92.1% (90.3%
to 93.9%) judged it not appropriate for doctors to prescribe
antibiotics. In the open placebo scenario (scenario 3; table 3),
84.9% (82.5% to 87.3%) of respondents thought that it was
acceptable for patients to be given placebo treatments to treat
chronic abdominal pain.
Placebo treatments, honesty, and trust
Several responses emphasize the value of physician honesty.
Specifically, in response to the first version of scenario 1 in
which physicians offer patients a placebo treatment for stomach
pain without indicating that it is a placebo treatment (box),
74.5% (70.4% to 78.7%) of respondents agreed that if the
treatment worked and patients asked what the medicine was,
the doctors should tell them it was a placebo. In the cold
symptom scenario (scenario 2), respondents were asked how
the patient’s future relationship with her doctor would be
affected if she later found out that she had been given a placebo
treatment. Nearly twice as many respondents thought that
discovering that she had received the placebo treatment, even
if it worked, would have a negative rather than positive effect
(53.9% (50.5% to 57.3%) v 28.5% (25.4% to 31.6%)) on the
future doctor-patient relationship; only 17.6% (15.0% to 20.2%)
thought that use of the placebo treatment would have no effect
on their future relationship. If the placebo treatment didn’t work,
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81.2% (78.5% to 83.8%) of respondents judged that this would
have a negative effect on the doctor-patient relationship.
Respondents were read scenario 4 (box) asking whether doctors
should give patients an honest opinion about a treatment the
doctors considered safe but no better than a placebo. When the
patient in the scenario had only read about the treatment but not
yet tried it, 63.3% (60.1% to 66.6%) of respondents definitely
thought doctors should give an honest assessment of the
treatment (table 4⇓), 49.6% (46.2% to 53.0%) when the
treatment had been recommended by a friend who thought it
had helped, and just 33.9% (30.7% to 37.1%) when patients
reported that they had been using the treatment and it seemed
to be helping. Moreover, if patients felt that they were receiving
benefit from using the treatment, 18.2% (15.7% to 20.8%) of
respondents thought that doctors should definitely not tell
patients that the treatment was no better than a placebo.
Willingness to try placebo treatments
Respondents randomized to the second version of scenario 1
(box) were asked if they would be willing to take a placebo
treatment for moderate stomach pain if they were aware that
the doctor was recommending a placebo treatment. Two thirds
of respondents (65.4%, 60.8% to 70.0%) said they would
probably (36.5%, 31.9% to 41.1%) or definitely (28.9%, 24.5%
to 33.2%) be willing to take the treatment under these conditions.
Similarly, in response to scenario 3 (box), over half of
respondents (61.5%, 58.2% to 64.8%) said they would probably
(30.9%, 27.8% to 34.0%) or definitely (30.6%, 27.5% to 33.7%)
take pills for chronic abdominal pain if they knew the pills were
placebo treatments intended to produce relief throughmind-body
self healing processes.
Discussion
The opinions of US patients have been missing from debates
over the use of placebo treatments in clinical practice and
deliberate efforts by physicians to enhance patient care by
promoting placebo responses. Our data show that patients are
open to the idea of placebo treatments. Most (50-84%) judged
it acceptable for doctors to recommend placebo treatments under
conditions that varied according to the doctor’s level of certainty
about the benefits of the treatment, the purpose of the treatment
(for example, to address a patient’s need to receive a treatment),
and the transparency with which the treatment was described
to patients. Fewer than a quarter stated that it was never
acceptable for doctors to recommend placebo treatments. In
addition, many respondents indicated a willingness to try
placebo treatments in different scenarios. This is generally
compatible with trends reported in previous patient surveys in
other countries regarding willingness to try placebo
treatments.16-18 20
Our findings also underscore the importance of honesty and
trust in the prescription of placebo treatments. Respondents
indicated that the use of placebo treatments could have a
negative impact on the doctor-patient relationship if patients
learnt that a doctor had recommended a placebo to placate
patient’s expectations for treatment–especially if it did not work.
Respondents said that doctors should be honest about an
intervention being a placebo treatment when patients ask specific
questions about the treatment, and they disagreed about whether
it is acceptable for physicians to call a placebo treatment “real
medicine.” Interestingly, some respondents thought that doctors
should not disclose that a treatment is a placebo if it is working,
suggesting some support for the non-transparent use of placebo
treatments, a finding not reported in previous surveys.
Although clinical practice guidelines recommend against the
use of placebo treatments to mollify patients,10most participants
in this survey judged their use to be acceptable to address
patients’ need to feel like they received some treatment. Patients
did, however, specify limits on how far physicians should go
to placate patients, with over 90% judging it inappropriate for
doctors to prescribe antibiotics for a cold, even when patients
ask for it. Yet recent surveys suggest that a small proportion of
physicians would indeed prescribe antibiotics to some patients
in this situation, and that they had done so at least once within
the past year.4 21 Taken together, these findings hint at a
disconnect between clinical practice guidelines, patients’
opinions, and physicians’ practices that should be further
explored.
Although our data indicate a general acceptance of placebo
treatments by patients, responses to different questions about
the effectiveness of such treatments varied.While most thought
when asked directly that placebo treatments are only effective
when patients do not know they are receiving them, the
responses to the more nuanced scenarios indicated a general
acceptance of transparently prescribed “open” placebo
treatments—both a belief that they are effective (62%) and a
willingness to take them (61-65%). This discrepancy prompts
questions about how well patients understand the concept of
placebo treatments in general and whether providing additional
detail in the scenarios adds to their understanding such that their
answers to the corresponding questions are more accurate.
The study sample was representative of the population of
Northern California but may not be representative of US patients
in general. Our sample wasmore highly educated (≥44% college
graduates) than the general population, had health insurance
coverage through Kaiser Permanente Northern California, and
had seen a physician within the past six months for a chronic
medical condition. Although we constructed our definition of
placebo treatments based on feedback from focus groups and
pretest interviews, respondents may none the less have variable
or limited understandings of the concepts of the placebo effect
and placebo treatments. This is perhaps not surprising, given
the variable understandings of these concepts among the placebo
research community.5 In view of the widespread variability in
definitions and conceptions of placebo in the literature, we
endeavored to employ a pragmatic definition of the placebo
effect in our questionnaire that would be useful in the context
of a patient survey. While there may be some vagueness and
ambiguity in the concept of placebo treatments, the pattern of
survey responses and our experience in exploring placebo
treatments with focus groups indicate that patients are able to
understand the difference between treatments that work on the
basis of their inherent pharmacologic properties and those that
may produce benefit primarily by means of positive
expectations. We observed some variability in answers to
analogous questions that were asked in different ways (for
example, directly versus in contextualized scenarios), and it is
difficult to know which formulation of the questions is likely
to reflect attitudes more accurately. Furthermore, the survey
captures patients’ opinions about a series of plausible
hypothetical scenarios rather than actual behaviors and
experiences.
Researchers of one study have argued that models of shared
decision making need to include conversations between
physicians and patients about the role of the placebo effect in
clinical care,22 and clinical practice guidelines leave the door
open for the use of placebo treatments when presented to patients
transparently.10 Researchers of another study further suggest
that attitudinal data can help develop and foster the use of
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effective and non-deceptive placebo treatment techniques.20
That many patients in this survey seem favorable to the idea of
placebo treatments suggests that physicians should consider
engaging with patients to discuss their values and attitudes
concerning the appropriateness of using placebos in the context
of clinical decision making. Such conversations could allow
physicians to determine which patients might be open to the
use of placebo treatments and could help physicians tailor their
description of placebo treatments according to patients’
preferences and level of understanding. Further research is
needed to determine how physicians can optimally promote
placebo responses in clinical practice and to guide the
appropriate use of placebo treatments.
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What is already known on this topic
The use of placebo treatments by physicians in clinical practice has been documented in recent surveys
Attitudinal surveys in other countries suggest that patients are open to the use of placebo treatments in specific circumstances
What this study adds
This study provides data on US patients’ attitudes about the use of placebo treatments in clinical practice
These data suggest that many patients are favorable to the idea of placebo treatments
Tables
Table 1| Demographic data. Values are number (percentage) of participants unless stated otherwise
Participants (n=853)Characteristics
524 (61.4)Women
329 (38.6)Men
Age group (years):
280 (32.8)18-35
408 (47.8)36-60
165 (19.3)≥61
45.1 (15.7)Mean (SD) age
Educational level:
13 (1.5)Less than high school graduate
107 (117.1)High school graduate
316 (37.4)Some college
372 (44.5)College degree or beyond
Race/ethnicity:
486 (57.7)White non-Hispanic
82 (9.7)African-American/other black
132 (15.7)Hispanic/Latino
121 (14.4)Asian non-Hispanic
4 (0.5)American Indian or Alaska Native
7 (0.8)Native Hawaiian or other Pacific Islander
10 (1.2)Mixed
Self reported health:
170 (20.1)Excellent
359 (42.4)Very good
234 (27.6)Good
69 (8.1)Fair
15 (1.8)Poor
*Based on Office of Management and Budget categories (www.whitehouse.gov/sites/default/files/omb/assets/information_and_regulatory_affairs/re_app-a-update.
pdf).
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Table 2| General opinions about placebo treatments*
Opinions (% of participants, 95% CI)
Statements Strongly disagreeSomewhat disagreeSomewhat agreeStrongly agree
10.7 (8.7 to 12.8)19.8 (17.1 to 22.5)49.4 (46.0 to 52.7)20.1 (17.4 to 22.8)Placebo treatments can produce physical changes
in the body
9.6 (7.6 to 11.6S)7.3 (5.6 to 9.1)14.3 (12.0 to 16.7)68.7 (65.6 to 71.9)For a placebo treatment to be effective, patients
cannot know that they are receiving a placebo
treatment
6.77 (5.0 to 8.3)12.4 (10.1 to 14.6)30.3 (27.2 to 33.4)50.7 (47.3 to 54.0)Placebo treatments can only be effective if patients
trust the physicians who recommend the treatment
39.4 (36.1 to 42.7)38.7 (35.4 to 42.0)10.5 (8.5 to 12.6)11.4 (9.2 to 13.5)Doctors should never recommend placebo
treatments to patients
11.3 (9.2 to 13.5)12.4 (10.2 to 14.6)44.3 (41.0 to 47.7)31.9 (28.8 to 35.1)It is acceptable for doctors to recommend a placebo
treatment if they believe the treatment will benefit
the patients and not cause harm
24.4 (21.5 to 27.3)25.6 (22.6 to 28.5)35.9 (32.6 to 39.1)14.2 (11.8 to 16.6)It is acceptable for doctors to recommend a placebo
treatment if they are uncertain about whether the
treatment will provide a benefit for patients, so long
as the doctors believes it is safe
16.8 (14.3 to 19.4)13.2 (10.9 to 15.5)39.1 (35.8 to 42.4)30.8 (27.7 to 34.0)In general, it is acceptable for doctors to offer a
safe placebo treatment if it addresses the patients’
need to feel like they are being given something to
get better†
32.6 (29.4 to 35.7)21.0 (18.3 to 23.8)25.9 (22.9 to 28.8)20.5 (17.8 to 23.3)If doctors recommend a placebo treatment, it is
acceptable for the doctors to tell the patients that
this treatment is a real medicine
*Placebo treatment was explained: “A patient experiences a placebo effect when they get better after taking a treatment, not because of the treatment itself, but
because the patient expects they will benefit from the treatment. For the rest of this survey, we will ask you to assume that a placebo treatment is a treatment that
only works because it can produce a placebo effect. Placebo treatments can be sugar pills or other treatments used to create a placebo effect.”
†Response options for this item were: definitely yes, probably yes, probably not, definitely not.
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Table 3| Acceptability of offering placebo treatments in different scenarios*
% of participants (95% CI)
Treatment scenarios Definitely notProbably notProbably yesDefinitely yes
20.1 (16.3 to 24.0)8.9 (6.2 to 11.6)40.0 (35.4 to 44.7)30.9 (26.5 to 35.3)Acceptable for doctors to try placebo treatments for stomach pain when patients
do not know doctors are recommending a placebo treatment? (Scenario 1, version
1) (n=427)
13.4 (10.1 to 16.6)8.1 (5.5 to 10.7)37.5 (32.8 to 42.1)41.1 (36.3 to 45.8)Acceptable for doctors to try a placebo treatment for stomach pain when patients
are aware that doctors are recommending a placebo treatment? (Scenario 1,
version 2) (n=419)
24.7 (21.8 to 27.6)9.70 (7.7 to 11.7)29.0 (25.9 to 32.0)36.6 (33.3 to 39.80)Acceptable for doctors to give patients placebo treatment for cold symptoms if
patients are told that they are getting medicine that is safe, has no side effects,
and helps some people get better when they take it? (Scenario 2)
81.0 (78.3 to 83.6)11.1 (9.0 to 13.2)5.2 (3.7 to 6.7)2.7 (1.6 to 3.8)Acceptable for doctors to recommend antibiotics for patients who want them to
treat cold symptoms that are likely to be caused by a viral infection? (Scenario 3)
7.8 (6.0 to 9.7)7.3 (5.5 to 9.0)27.3 (24.3 to 30.4)57.6 (54.2 to 60.9)Acceptable for doctors to give patients placebo pills for abdominal pain if patients
are told they are getting placebo medicine to produce relief through mind-body self
healing processes? (Scenario 3)
*See box for detailed scenarios.
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Table 4| Scenarios for query on whether doctors should tell patients when they think a treatment is safe but no better than a placebo*
% of participants (95% CI)
Scenarios Definitely notProbably notProbably yesDefinitely yes
5.6 (4.0 to 7.2)8.3 (6.5 to 10.2)22.7 (19.9 to 25.6)63.3 (60.1 to 66.6)If patients tell the doctor that they read about the treatment on the internet or in a
magazine but have not tried it yet
8.1 (6.2 to 9.90)14.6 (12.2 to 17.0)27.7 (24.7 to 30.7)49.6 (46.2 to 53.0)If patients tell the doctor that a good friend is using the treatment and felt it was
really helping
18.2 (15.6 to 20.8)25.4 (22.4 to 28.3)22.5 (19.7 to 25.3)33.9 (30.7 to 37.1)If patients tell the doctor that they have been using the treatment for the past two
weeks and it seems to be helping
*See box, scenario 4.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f3757 doi: 10.1136/bmj.f3757 (Published 2 July 2013) Page 9 of 9
RESEARCH
